{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-006886","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.747331+00:00","generated_at":"2026-06-26T20:38:18.975979+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exagen reports FY 2021 revenue up 15% to $48.3M; guides FY 2022 revenue $51-53M","bullets":["Record 128,246 AVISE CTD tests in 2021; Q4 2021 test volume 34,147 (+21% YoY).","Full-year testing revenue $47.1M (+27.8% YoY); Q4 testing revenue $12.5M (+14.2% YoY).","FY 2021 net loss $26.9M vs $16.7M in 2020; cash $99.4M at year-end.","Guidance: FY 2022 revenue $51M-$53M, implying 6-10% growth over 2021.","Added Centene/WellCare coverage for 22M lives; now 91M in-network lives; acquired AVISE RADR license."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-006886","json":"https://secwatch.observer/filing/0001628280-22-006886.json","markdown":"https://secwatch.observer/filing/0001628280-22-006886.md","text":"https://secwatch.observer/filing/0001628280-22-006886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/0001628280-22-006886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/exdx-20220322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:38:18.975979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}